A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

(Reuters) -Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...